Need a mesothelioma lawyer? We will fight for you!
› $150,000,000 verdict in personal injury case
Yet another biotech company is diligently working to find a safer, less invasive test besides a colonoscopy to detect cancers of the colon and rectum. EDP Biotech Corporation of West Knoxville, Tenn., has announced that it is seeking FDA approval of a blood test to detect colon cancer at its earliest and most treatable stages.
The rate of new colorectal cancer cases and deaths from colorectal cancers has declined, according to a report from leading health and cancer organizations. Colorectal cancer is the third most common cancer among men and women, and the second leading cause of cancer deaths in the United States.
Colonoscopies are serious business. The procedure involves sending a small camera inside the colon to search for abnormalities, including colon or rectal cancers, also known as colorectal cancer. Regular colon screenings can find polyps even before they become cancerous. By removing those polyps, one can literally dodge colorectal cancer.
Colorectal cancer, or cancers of the colon or rectum, is the third most common cancer diagnosed in both men and women and the second leading cause of cancer-related deaths in the United States among men and women combined, according to the American Cancer Society. The average person has about a 1 in 19 risk of developing the disease over his lifetime. Detected early, the disease can be curable. The best defense is regular screenings. Regular colonoscopies are recommended beginning at age 50, or sooner for those with a family history or exhibiting symptoms.
![[ Beasley Allen Law Firm Logo ]](http://www.fleetattorney.net/wp-content/themes/system-unity/images/logo.png){kind=logo}